- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06074172
The Effect of Cannabidiol in Learning and Memory of Adults
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Using a randomized, double-blind, placebo-controlled two-arm case-crossover trial, this study investigates the effect of 246 milligrams (mg) of Cannabidiol (CBD) on the learning and memory scores of human subjects, as well as the effect of Cannabidiol on Proactive and Retroactive Interference. This study also investigated the influence of demographic factors on CBD's modulation of human learning and memory.
This study was conducted at Colorado State University-Pueblo (CSU Pueblo) with volunteers recruited from CSU Pueblo and the local Pueblo community. Fifty-seven subjects were randomized in a double-blind manner to receive either CBD or placebo before completing two versions of learning and memory assessments. Each version of the learning and memory assessment included the Montreal Cognitive Assessment (MOCA), the Rey Auditory Verbal Learning Task-Revised (RAVLT-R), and the Logical Memory Subject of the Weschler Memory Scale. Several components of the RAVLT-R were evaluated including the Sum of Trials (Trials I-V) score, Proactive Interference Ratio (PI Ratio), and Retroactive Interference (RI Ratio).
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Colorado
-
Pueblo, Colorado, United States, 81001
- Colorado State University Pueblo
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Were 18 years of age or older
Exclusion Criteria:
- Were pregnant or breast-feeding
- Had been diagnosed with mental illness
- Didn't speak English fluently
- Had severe hearing problems
- Had recreational or opioid drug contaminants in their urine
- Were involved in criminal activity
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo, Then Cannabidiol
Participants first received a Placebo 246 mg press pill during visit 1.
After a washout period of 1 week, subjects received a Cannabidiol press pill during visit 2.
|
Placebo press pills were provided by Steve Goods CBD (Longmont, Colorado).
Placebo pills were tested by the chemistry lab at CSU Pueblo and by Botanacar in Denver, CO.
Both laboratories determined placebo pills to be pure with no heavy metals, bacteria, and pesticides detected.
|
|
Active Comparator: Cannabidiol, Then Placebo
Participants first received a Cannabidiol 246 mg press pill during visit 1.
After a washout period of 1 week, subjects received a Placebo press pill during visit 2.
|
Cannabidiol press pills provided by Steve Goods CBD (Longmont, Colorado).
CBD pills were tested by the chemistry lab at CSU Pueblo and by Botanacor in Denver, CO.
Both laboratories determined CBD pills to be 99.98% pure with no THC, heavy metals, bacteria, and pesticides detected.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proactive Interference Ratio (PI Ratio)
Time Frame: Each trial is 45 seconds for encoding and recall
|
PI Ratio = Trial B1/A1.
Proactive interference is the tendency for previously learned information to affect to hinder learning of new information.
A higher proactive interference ratio indicates protective effects on memory i.e. protection from interference during learning.
A lower proactive interference is indicative of negative effects on memory caused from interference.
Trial A1 is in reference to list A recall during the first trial.
Trial B1 is in reference to list B recall.
Highest score for each trial is 15 with a point awarded for each correctly recalled word from List A (15 words) and List B (15 words).
|
Each trial is 45 seconds for encoding and recall
|
|
Retroactive Interference Ratio (RI Ratio)
Time Frame: Each trial is 45 seconds for encoding and recall
|
RI Ratio = Trial A6/A5.
Retroactive interference is the tendency for newly learned information to hinder the memory of previously learned information.
A higher retroactive interference ratio indicates protection from interference during learning.
A lower retroactive interference ratio is indicative of negative effects on memory caused from interference.
Trial A6 is referring to delayed recall of list A; Trial A5 is referring to the fifth trial of list A recall.
Highest score for each trial is 15 with a point awarded for each word correctly recalled from List A (15 words).
|
Each trial is 45 seconds for encoding and recall
|
|
Total Prose Recall
Time Frame: Each recall takes about 5 min for encoding and recall
|
Total Prose Recall = Immediate Recall + Delayed Recall; Recall of a prose story was done immediately then after a delay; Highest score for prose recall test is 25 with a point awarded for each item correctly recalled in the story (25 total items).
A higher recall score is indicative of better memory.
|
Each recall takes about 5 min for encoding and recall
|
|
Sum of Trials (I-V)
Time Frame: Each trial is 45 seconds for encoding and recall
|
Sum of Trials = Trial A1 + Trial A2 + Trial A3 + Trial A4 + Trial A5; Trial A1/A2/A3/A4/A5 are in reference to each trial in which list A is recalled during memory encoding. The score range for Sum of Trials is 0 to 75. A higher score is indicative of greater performance on the memory test and a lower score is indicative of lower performance on the memory test. Participants were instructed to listen to a list of 15 words (List A) read to them. Subjects were asked recall List A during five different trials (A1, A2, A3, A4, A5), with the words repeated to them after each trial. Participants were scored for the number of correctly repeated words for each trial. |
Each trial is 45 seconds for encoding and recall
|
|
Montreal Cognitive Assessment Score
Time Frame: 10 minutes total for encoding and recall
|
Assessment of basal cognitive function; The range for Montreal Cognitive Assessment (MOCA) scores is 0 to 30.
A higher recall score is indicative of better performance on the memory test.
A lower recall score is indicative of worse performance on the memory test.
|
10 minutes total for encoding and recall
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Moussa M Diawara, PhD, Colorado State University-Pueblo
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MD012420BM
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Memory
-
Kutahya Health Sciences UniversityCompletedWorking Memory | The Working Memory QuestionnaireTurkey
-
Prof. Dominique de Quervain, MDClinical Trial Unit, University Hospital Basel, SwitzerlandCompletedMemory, Short-Term | Memory, Long-TermSwitzerland
-
Dream Video LLCDream Holdings ResearchNot yet recruitingMemory | Habits | Behavior Change Interventions | Memory Encoding
-
EnzymedicaKGK Science Inc.CompletedMemory | Self-reported Memory ProblemsCanada
-
Memorial Sloan Kettering Cancer CenterCompletedMemory Losses | Amnesia-Memory LossUnited States
-
University of Electronic Science and Technology...CompletedOxytocin Effect on Memory Performance During Phase 1 | Oxytocin Effect on Memory Performance During Phase 2 | Oxytocin Effect on Memory Performance During Phase 3 | Oxytocin Effect on Memory Performance During Phase 4China
-
University of Maryland, College ParkUniversity of Massachusetts, AmherstRecruiting
-
Virginia Polytechnic Institute and State UniversityEnrolling by invitation
-
University of PennsylvaniaNational Institute of Mental Health (NIMH)Completed
-
Prof. Dominique de Quervain, MDCompleted
Clinical Trials on Placebo (246mg press pill)
-
China Medical University HospitalCompleted
-
China Medical University HospitalRecruitingDelirium | Agitation | Intensive Care Unit DeliriumTaiwan
-
University of Alabama at BirminghamCompletedObesity | Body Weight | Eating Behavior | HungerUnited States
-
Massachusetts General HospitalGaneden Biotech, Inc.TerminatedIrritable Bowel Syndrome | Major Depressive DisorderUnited States
-
University Hospital, BonnRecruitingSymptomatic EpilepsyGermany
-
University of UtahThe Depressive and Bipolar Disorder Alternative Treatment FoundationCompletedBipolar Disorder | Bipolar Depression | Manic DepressionUnited States
-
Peking Union Medical College HospitalThe Second Hospital of Hebei Medical University; China-Japan Friendship Hospital and other collaboratorsUnknownAcute Ischemic StrokeChina
-
Tasly Pharmaceutical Group Co., LtdRecruiting
-
Tongji HospitalRecruitingPerimenopausal SyndromeChina
-
Shanghai Hutchison Pharmaceuticals LimitedRecruitingAngina Pectoris | Coronary Heart Disease | Non Obstructive Coronary Artery Disease | X Syndrome, AnginaChina